Boceprevir Disease Interactions

Anemia, neutropenia and thrombocytopenia has been reported with the use of boceprevir. Boceprevir is always administered with peginterferon alfa and ribavirin which are also associated with pancytopenia. The addition of boceprevir has shown an additional decrease in hemoglobin and blood cell counts. Caution should be used in patients with preexisting anemia, neutropenia or thrombocytopenia. A complete blood count should be obtained pretreatment, and then during treatment at weeks 2, 4, 8, and 12. Patients should be monitored closely. Refer to the prescribing information for peginterferon alfa and ribavirin for additional information regarding dose reduction or discontinuation based on laboratory parameters. If ribavirin and peginterferon alfa need to be discontinued, boceprevir should be discontinued as well.